Protocol Ledger

NCT06592274 · Phase II · COMPLETED

A Phase 2 Study of HB0017 in Psoriasis Patients

Interventional Phase II clinical trial protocol NCT06592274 sponsored by Huabo Biopharm Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-30 Enrollment: 206 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06592274
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)206 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06592274
Protocol FieldVerified Registry Value
NCT IdentifierNCT06592274
Consolidated Lead SponsorHuabo Biopharm Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment206 participants (ACTUAL)
Registered Start Date2024-09-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI